Atle Fund Management AB Sells 6,111 Shares of Eli Lilly and Company $LLY

Atle Fund Management AB decreased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 16.4% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 31,133 shares of the company’s stock after selling 6,111 shares during the quarter. Eli Lilly and Company comprises about 10.6% of Atle Fund Management AB’s investment portfolio, making the stock its biggest position. Atle Fund Management AB’s holdings in Eli Lilly and Company were worth $33,458,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in LLY. Capital Research Global Investors boosted its holdings in shares of Eli Lilly and Company by 20.9% during the third quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock worth $19,141,787,000 after purchasing an additional 4,332,008 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Eli Lilly and Company by 1.2% in the fourth quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company’s stock valued at $88,087,193,000 after acquiring an additional 1,006,885 shares during the last quarter. Amundi boosted its holdings in Eli Lilly and Company by 27.1% in the third quarter. Amundi now owns 4,525,902 shares of the company’s stock valued at $3,823,977,000 after acquiring an additional 964,675 shares during the last quarter. Jennison Associates LLC boosted its holdings in Eli Lilly and Company by 22.3% in the fourth quarter. Jennison Associates LLC now owns 5,133,676 shares of the company’s stock valued at $5,517,059,000 after acquiring an additional 937,204 shares during the last quarter. Finally, Victory Capital Management Inc. boosted its holdings in Eli Lilly and Company by 47.6% in the third quarter. Victory Capital Management Inc. now owns 2,309,006 shares of the company’s stock valued at $1,761,772,000 after acquiring an additional 744,868 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on LLY. TD Cowen lifted their target price on Eli Lilly and Company from $960.00 to $1,250.00 and gave the company a “buy” rating in a report on Thursday, January 29th. Berenberg Bank boosted their price objective on Eli Lilly and Company from $950.00 to $1,050.00 and gave the stock a “hold” rating in a research note on Thursday, February 19th. The Goldman Sachs Group boosted their price objective on Eli Lilly and Company from $1,260.00 to $1,283.00 and gave the stock a “buy” rating in a research note on Friday, May 1st. Scotiabank restated an “outperform” rating and set a $1,300.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, February 5th. Finally, Guggenheim restated a “buy” rating and set a $1,183.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, May 5th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,218.33.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Analysts and market commentary continue to highlight Eli Lilly’s leadership in the obesity boom, with strong sales momentum in key products such as Mounjaro and broader confidence that the company still has room to run. Article Title
• Positive Sentiment: Stat News reported that Eli Lilly tops prominent rankings for pharma R&D performance, reinforcing the view that the company’s pipeline and innovation engine remain among the best in the industry. Article Title
• Positive Sentiment: Eli Lilly also announced it completed a key olomorasib drug-interaction study, which helps clarify next steps for its KRAS pipeline and supports the long-term growth story beyond obesity drugs. Article Title
• Neutral Sentiment: The company will participate in Bernstein’s Strategic Decisions Conference later this month, a routine investor-relations event that could provide more details on strategy and pipeline updates. Article Title
• Negative Sentiment: The U.S. Supreme Court declined to hear Eli Lilly’s appeal in a Medicaid whistleblower case, leaving in place a roughly $194 million award and keeping legal/compliance risk in focus. Article Title
• Negative Sentiment: Related coverage noted that the ruling could raise scrutiny around Medicaid rebates and dividend implications, adding a modest overhang even as the core business remains strong. Article Title

Eli Lilly and Company Stock Up 3.0%

Shares of Eli Lilly and Company stock opened at $1,017.68 on Wednesday. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. The firm has a market cap of $958.39 billion, a P/E ratio of 36.15, a P/E/G ratio of 1.07 and a beta of 0.48. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,133.95. The business has a 50-day moving average price of $940.54 and a 200 day moving average price of $1,000.84.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating the consensus estimate of $6.97 by $1.58. The firm had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.Eli Lilly and Company’s quarterly revenue was up 55.5% on a year-over-year basis. During the same period in the previous year, the company earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, sell-side analysts forecast that Eli Lilly and Company will post 35.82 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be issued a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. Eli Lilly and Company’s dividend payout ratio is 24.58%.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.